October 2, 2023 Disclosure to EGX regarding the appointment of Khaled Daader as Head of Investor Relations and Mergers and Acquisitions Q3 2023 PDF
July 16, 2023 Disclosure to EGX regarding the failure to reach quorum for the company’s EGM Q2 2023 PDF
July 16, 2023 Disclosure to EGX regarding the failure to reach quorum for the company’s EGM Q2 2023 PDF
June 1, 2023 Disclosure regarding Rameda acquiring a selection of pharmaceutical products belong to diabetes and cholesterol treatment drugs Q2 2023 PDF
December 20, 2022 Disclosure regarding Rameda acquiring exclusive rights for the distribution and marketing of “Physiomer” in Egypt Q4 2022 PDF
August 21, 2022 Disclosure to EGX regarding the inauguration of a new water treatment station Q3 2022 PDF
April 7, 2022 Disclosure to the Egyptian Stock Exchange regarding the distribution of dividends Q2 2022 PDF
March 22, 2021 Disclosure to EGX correcting the number of BoD meetings in the Annual BoD Report Q1 2021 PDF
February 9, 2021 Disclosure to EGX on GlaxoSmithKline S.A.E response to Rameda’s acquisition request Q1 2021 PDF
February 2, 2021 Disclosure to EGX on Rameda expressing interest in the acquisition of GlaxoSmithKline S.A.E Q1 2021 PDF
November 25, 2020 Disclosure to EGX regarding the contact information for Investor Relations department Q4 2020 PDF
September 17, 2020 Disclosure to EGX regarding the failure to reach quorum for the company’s EGM Q3 2020 PDF
June 22, 2020 EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Q2 2020 PDF
April 1, 2020 EGX disclosure announcing the acquisition of a generic anti-inflammatory analgesic molecule Q2 2020 PDF
January 14, 2020 Disclosure to EGX on BOD and shareholding structure as of 31 December 2019 Q1 2020 PDF
